



NEWS UPDATE

Spirify Pharma, Inc. appoints Alexander Kraus to Chief Business Officer

Naples, FL, October 12, 2021.

Appointment of experienced pharma executive further strengthens Spirify's leadership team

Spirify Pharma, Inc. ("Spirify"), a pharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in CNS diseases, today announced it has appointed Alexander Kraus, PhD to the newly created position of Chief Business Officer. Dr. Kraus' role will include business and corporate development, licensing, and strategic planning.

Dr. Kraus has over twenty years of experience in the biopharmaceutical industry in both the U.S. and Europe in R&D, business, and corporate development roles. Dr. Kraus started his career at German pain specialty company Grünenthal GmbH in 1999. During his tenure from 2001 to 2009 as Head of Pharmacokinetics at Grünenthal he was part of the preclinical and clinical stage gate committees for development candidate selection and contributed significantly to the development and European approval of various products like buprenorphine transdermal patch (TRANSTEC®), lidocaine hydrogel patch (VERSATIS®), and tapentadol (PALEXIA®). After relocating to the US in 2009, Dr. Kraus held different commercial and business development roles and was responsible for marketing and partnering of selected Grünenthal products and technologies in the US market.

Since 2017, Dr. Kraus has worked with several companies as a consultant and held a position as Head of Search&Evaluation at Aquestive Therapeutics, a specialty CNS pharmaceutical company with a focus in epilepsy, located in Warren, New Jersey. In April of 2020 Dr. Kraus relocated back to Germany and is working as consultant and interim manager.

In addition to his work with Spirify Pharma, Dr. Kraus holds position as Senior Advisor with Princeton Capital Advisors, a global cross-border transaction advisory and strategy consulting for health care, pharmaceutical and biotech firms, and is a Member of the Scientific Advisory Board at Enalare Therapeutics, a privately owned clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from acute respiratory conditions. He also is a business advisor to small startup and biotech companies with BaselArea Swiss/BaseLaunch accelerator in Basel. Dr. Kraus holds a PhD in Chemistry from University of Cologne, Germany.

About Spirify Pharma, Inc.

Spirify Pharma, Inc. is a pharmaceutical company dedicated to transforming the way pain and depression are treated by developing novel therapeutics based on HNK derivative compounds. Spirify is based in Naples, Florida. More information can be found by visiting the Spirify website at www.spirifypharma.com.

Spirify Contact:

Sigal Kremer-Tal, MD - CEO & Co-founder
stal@spirifypharma.com

Alexander Kraus, PhD - CBO
akraus@spirifypharma.com